This paper examines PGAM5, a mitochondrial phosphatase, as a potential therapeutic target in amyotrophic lateral sclerosis (ALS), focusing on its role in activating the stress-regulated peptidase OMA1 and the downstream mitochondrial integrated stress response (ISR) in motor neurons.
Zheng et al. identify that PGAM5 dephosphorylates and activates OMA1, triggering a maladaptive mitochondrial integrated stress response in motor neurons across multiple ALS subtypes — positioning PGAM5 as a novel, broadly applicable target.
The abstract provides limited methodological detail; it is unclear whether findings are validated in human tissue or only in animal/cell models, and no clinical or functional outcome data are reported.
No immediate clinical action is warranted, but PGAM5 inhibition represents a potentially subtype-agnostic strategy in ALS drug development worth monitoring as preclinical work matures.
